The North America deferasirox market is witnessing continued demand as healthcare systems focus on long-term management of transfusional iron overload and related hematological disorders. Increasing diagnosis and monitoring of conditions such as thalassemia and sickle cell disease, together with the preference for convenient oral chelation therapy, is supporting the use of deferasirox....